Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

被引：4
|
作者：
Breccia, Massimo [1 ]
Santopietro, Michelina [1 ]
Loglisci, Giuseppina [1 ]
Stagno, Fabio [2 ,3 ]
Cannella, Laura [1 ]
Carmosino, Ida [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Dept Human Biotechnol & Hematol, I-00161 Rome, Italy
[2] Univ Catania, Dept Biomed Sci, Hematol Sect, Catania, Italy
[3] Univ Catania, Gen Pathol Sect, Catania, Italy
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 08期
关键词：
Chronic myeloid leukemia; Imatinib; Warfarin;
D O I：
10.1016/j.leukres.2010.03.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E224 / E225
页数：2
相关论文
共 50 条
  • [41] Safety and Efficacy of Flumatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Imatinib
    Liu, Yuntao
    Yang, Yunfan
    Sun, Hui
    Meng, Li
    Lin, Hai
    Chen, Chunyan
    Hu, Jianda
    Shen, Xuliang
    Duan, Minghui
    Zhang, Yanli
    Abulaiti, Dilinazi
    Wang, Jinghua
    Zhu, Hongqian
    Hua, Luoming
    Leng, Qing
    Zhang, Chun
    Sun, Lili
    Li, Weiming
    Zhu, Huanling
    Liu, Bingcheng
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [42] The efficacy of generic imatinib in patients with chronic myeloid leukemia - a single center experience
    Urosevic, Ivana
    Percic, Ivanka
    Jojkic, Marina Dragicevic
    Dokic, Marina
    El Farra, Amir
    Savic, Aleksandar
    Milosevic, Ivana
    Vlaisavljevic, Nada
    Sekulic, Borivoj
    Balint, Bela
    VOJNOSANITETSKI PREGLED, 2021, 78 (05) : 526 - 531
  • [43] Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia
    Takami, Akiyoshi
    Ohtake, Shigeki
    Morishita, Eriko
    Terasaki, Yasushi
    Fukushima, Toshihiro
    Kurokawa, Toshiro
    Sugimori, Naomi
    Matano, Sadaya
    Ohata, Kinya
    Saito, Chizuru
    Yamaguchi, Masaki
    Hosokawa, Kohei
    Yamazaki, Hirohito
    Kondo, Yukio
    Nakao, Shinji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (03) : 357 - 363
  • [44] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
  • [45] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    J Cortes
    D-W Kim
    E Raffoux
    G Martinelli
    E Ritchie
    L Roy
    S Coutre
    S Corm
    N Hamerschlak
    J-L Tang
    A Hochhaus
    H J Khoury
    T H Brümmendorf
    M Michallet
    G Rege-Cambrin
    C Gambacorti-Passerini
    J P Radich
    T Ernst
    C Zhu
    J M A Van Tornout
    M Talpaz
    Leukemia, 2008, 22 : 2176 - 2183
  • [46] Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia
    Demirkan, Fatih
    Sevindik, Omur Gokmen Gokmen
    Karaman, Aysegul
    Alacacioglu, Inci
    Solmaz, Serife Medeni
    Ozsan, Guner Hayri
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
    Miura, Masatomo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (05) : 645 - 654
  • [48] Development and validation of a nomogram to predict poor efficacy of imatinib in the treatment of newly diagnosed chronic phase chronic myeloid leukemia patients
    Li, Yuxin
    Zhang, Yilin
    Wang, Jin
    He, Aili
    Zhang, Wanggang
    Cao, Xingmei
    Chen, Yinxia
    Liu, Jie
    Zhang, Pengyu
    Wang, Jianli
    Zhao, Wanhong
    Yang, Yun
    Meng, Xin
    Chen, Sheping
    Zhang, Longjin
    Wang, Ting
    Wang, Xugeng
    Ma, Xiaorong
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [49] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
  • [50] Tolerability and Efficacy of Pegylated Interferon-α-2a in Combination With Imatinib for Patients With Chronic-Phase Chronic Myeloid Leukemia
    Johnson-Ansah, Hyacinthe
    Guilhot, Joelle
    Rousselot, Philippe
    Rea, Delphine
    Legros, Laurence
    Rigal-Huguet, Francoise
    Nicolini, Franck Emmanuel
    Mahon, Francois-Xavier
    Preudhomme, Claude
    Guilhot, Francois
    CANCER, 2013, 119 (24) : 4284 - 4289
12345